Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Baum

Showing results (171-180 of 172) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 172 results.
Antiviral Therapy|March 21, 2000
Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study GroupL E Chapman, G J Mertz, C J Peters, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2002
Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndromeL E Chapman, B A Ellis, F T Koster, et al.
Pageof 18

Showing results (171-180 of 172) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 172 results.
Antiviral Therapy|March 21, 2000
Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study GroupL E Chapman, G J Mertz, C J Peters, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2002
Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndromeL E Chapman, B A Ellis, F T Koster, et al.
Pageof 18